: Cadila Healthcare on Saturday said its group firm Zydus Cadila has received the final approval from the US health regulator to market blood pressure medicine - Amlodipine and Olmesartan Medoxomil tablets. The nod by US Food and Drug Administration (FDA) is for multiple strengths of the tablets 5mg/40mg; 10mg/20mmg and 10mg/40 mg, the company said in a filing to the Bombay Stock Exchange (BSE). "The drug is indicated for the treatment of hypertension, alone or with other anti-hypertensive agents to lower blood pressure and will be manufactured at the group's formulations manufacturing facility at Pharma SEZ Ahmedabad," Cadila Healthcare added.
The group has now more than 150 approvals and has so far filed over 300 abbreviated new drug applications (ANDAs) since the commencement of filing process in FY2003-04, it added.
Election Results for Lok Sabha Election 2019 will be out on May 23. Get the latest election news and live updates on ndtv.com/elections. Catch all the action on NDTV Live. Like us on Facebook or follow us on Twitter and Instagram for news updates from each of the 543 parliamentary seats for the election 2019